Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH434 Open-Label Extension in Multiple System Atrophy
NCT07729852Phase 2Enrolling by invitation
- Sponsor
- Alterity Therapeutics
- Start
- Oct 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ATH-434 in multiple system atrophy (MSA), sponsored by Alterity Therapeutics. Started Oct 2026; status: enrolling by invitation.
02
Drugs
ATH-434
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07729852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729852.